Huanyu Meng

Huanyu Meng

Auto-generated profile, based on publicly available information

Huanyu Meng

Department of Neurology and Institute of Neurology, Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in Radiology
Verified
Journal Article
Closed access
MZMin Zhang
Min Zhang
HMHuanyu Meng
Huanyu Meng
QZQinming Zhou
Qinming Zhou
HCHangxing Chunyu
Hangxing Chunyu
LHLu He
Lu He
Sheng ChenSheng Chen
Sheng Chen
Background Translocator protein (TSPO) PET has been used to visualize microglial activation in neuroinflammation and is a potential imaging tool for detecting autoimmune encephalitis (AIE). Purpose To compare the detection rate between TSPO radioligand fluorine 18 (18F) DPA-714 PET and conventional MRI and assess the relationship between 18F-DPA-714 uptake and clinical features in participants with AIE. Materials and Methods Healthy volunteers and patients with AIE were enrolled in this prospective study between December 2021 and April 2023. All participants underwent hybrid brain 18F-DPA-714 PET/MRI and antibody testing. Modified Rankin scale scoring and AIE-related symptoms were assessed in participants with AIE. Positive findings were defined as intensity of 18F-DPA-714 uptake above a threshold of the mean standardized uptake value ratio (SUVR) plus 2 SD inside the corresponding brain regions of healthy controls. The McNemar test was used to compare the positive detection rate between the two imaging modalities; the independent samples t test was used to compare continuous variables; and correlation with Bonferroni correction was used to assess the relationship between 18F-DPA-714 uptake and clinical features. Results A total of 25 participants with AIE (mean age, 39.24 years ± 19.03 [SD]) and 10 healthy controls (mean age, 28.70 years ± 5.14) were included. The positive detection rate of AIE was 72% (18 of 25) using 18F-DPA-714 PET compared to 44% (11 of 25) using conventional MRI, but the difference was not statistically significant (P = .065). Participants experiencing seizures exhibited significantly higher mean SUVR in the entire cortical region than those without seizures (1.23 ± 0.21 vs 1.15 ± 0.18; P = .003). Of the 13 participants with AIE who underwent follow-up PET/MRI, 11 (85%) demonstrated reduced uptake of 18F-DPA-714 accompanied by relief of symptoms after immunosuppressive treatment. Conclusion 18F-DPA-714 PET has potential value in supplementing MRI for AIE detection. Clinical trial registration no. NCT05293405 © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Zaharchuk in this issue.

8 May 2020 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
JHJUAN HUANG
JUAN HUANG
HMHuan-Yu Meng
Huan-Yu Meng
XDXian Duan
Xian Duan
Wenwen LiWenwen Li
Wenwen Li
HXHongWei Xu
HongWei Xu
LZLin Zhou
Lin Zhou
Stiff limb syndrome (SLS) is a rare autoimmune-related central nervous system disorder, resulting in stiffness and spasms of limbs since onset with rare involvement of the truncal muscles. However, SLS patients will gain notable effects by appropriate therapy focusing on symptomatic treatment and immunotherapy. We reported on a 55-year-old female who showed typical painful spasms in both lower limbs and abduction of the right eyeball partially responded to low-dose diazepam and had high-titer anti-GAD antibody. EMG only showed CMUA in the anterior tibialis and right triceps. Eventually, our patient was diagnosed with SLS and treated with intravenous immunoglobulin (IVIG) and glucocorticoid combined simultaneously. She obtained notable effects. We also review and summarize the current literature on clinical characteristics, coexisting disease, treatment and outcome of 40 patients with SLS. We hope that this report will provide a basis for further understanding of SLS and promote the formation of more advanced diagnosis and treatment processes.

27 December 2023
Verified
Journal Article
Open access
PDF file
YLYizhou Lu
Yizhou Lu
LHLu He
Lu He
HMHuanyu Meng
Huanyu Meng
Sheng ChenSheng Chen
Sheng Chen
QZQinming Zhou
Qinming Zhou
Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease that is associated with selective and progressive loss of motor neurons. As a consequence, the symptoms of ALS are muscle cramps and weakness, and it eventually leads to death. The general markers for early diagnosis can assist ALS patients in receiving early intervention and prolonging their survival. Recently, some novel approaches or previously suggested methods have validated the potential for early diagnosis of ALS. The purpose of this review is to summarize the status of current general markers discovery and development for early diagnosis of ALS, including genes, proteins neuroimaging, neurophysiology, neuroultrasound, and machine learning models. The main genetic markers evaluated are superoxide dismutase 1 (SOD1), chromosome 9 open reading frame 72 (C9orf72), transactivation-responsive DNA binding protein 43 (TARDBP), and fused in sarcoma (FUS) genes. Among proteins, neurofilament light chain is still the most established disease-specific adaptive change in ALS. The expression of chitinases, glial fibrillary acidic protein (GFAP), and inflammatory factors are changed in the early stage of ALS. Besides, more patient-friendly and accessible feature assays are explored by the development of neuroimaging, neurophysiology, and neuroultrasound techniques. The novel disease-specific changes exhibited the promising potential for early diagnosis of ALS. All of these general markers still have limitations in the early diagnosis, therefore there is an urgent need for the validation and development of new disease-specific features for ALS.

13 September 2026 in Neuroprotection
Verified
Journal Article
Open access
PDF file
HMHuanyu Meng
Huanyu Meng
STSiqi Tu
Siqi Tu
YZYifan Zhou
Yifan Zhou
RSRuinan Shen
Ruinan Shen
XCXiaoyu Chen
Xiaoyu Chen
SCSheng Chen
Sheng Chen
Background: Efgartigimod disrupts the recycling of pathogenic IgG autoantibodies and may represent a candidate therapy for autoimmune encephalitis. This real‐world study evaluated the clinical efficacy, safety, and impact of efgartigimod on brain inflammation. Methods: This multicenter, single‐arm, prospective, observational real‐world study enrolled 18 patients, including 10 with anti‐N‐methyl‐ d ‐aspartate receptor (NMDAR) encephalitis and 8 with anti‐leucine‐rich glioma‐inactivated 1 (LGI1) encephalitis. Participants received intravenous efgartigimod at a dose of 10 mg/kg weekly for a total of two to four doses, with or without concomitant immunosuppressive therapy. Anti‐NMDAR‐IgG/LGI1‐IgG antibody titers, modified Rankin scale (mRS), Clinical Assessment Scale in Autoimmune Encephalitis (CASE), Montreal Cognitive Assessment, Mini‐Mental State Examination, and Glasgow Coma Scale scores were assessed at baseline and at 1, 2, 3, 8, and 12 weeks after treatment. 18 F‐DPA714 positron emission tomography/magnetic resonance imaging was used to monitor brain inflammation in a subset of patients. Analyses were performed using SPSS 26.0 and Prism 10.0. Non‐parametric tests, including Wilcoxon signed‐rank, Mann–Whitney U , and Friedman tests with Bonferroni post hoc correction, were applied. Two‐tailed p < 0.05 indicated statistical significance; corrected p < 0.01 was applied for five longitudinal pairwise comparisons. Results: At the final follow‐up, median mRS scores in patients with anti‐NMDAR encephalitis decreased significantly from 3 (range, 1–5) before treatment to 1 (range, 0–3) after treatment ( Z = −2.588, p = 0.007). Median CASE scores decreased from 7.5 (range, 1–27) to 1.5 (range, 1–7) post‐treatment ( Z = −2.714, p = 0.005). In patients with anti‐LGI1 encephalitis, CASE scores decreased markedly from 3 (range, 1–7) to 1.5 (range, 0–2) at the last visit ( Z = −2.154, p = 0.046). All 18 patients underwent baseline imaging, and 7 patients underwent follow‐up PET/MRI examinations. A subset of patients ( n = 4; three with anti‐NMDAR encephalitis and one with anti‐LGI1 encephalitis) showed reduced uptake in specific brain regions accompanied by symptom improvement. Both initial and follow‐up imaging results were negative for the remaining three patients. Comparative analysis of efgartigimod monotherapy versus combination therapy with glucocorticoids and immunosuppressants revealed no significant differences in key outcomes, indicating that the therapeutic effect was independent of concomitant medication use. Efgartigimod was well tolerated. One patient (1/18) developed mild pneumonia, but no other serious adverse events were reported. Conclusion: Efgartigimod may represent a novel therapeutic option for anti‐NMDAR and anti‐LGI1 encephalitis, potentially improving clinical outcomes in affected patients. Registration Info: This study was registered at the National Clinical Research Center ( https://www.medicalresearch.org.cn ; No. MR‐31‐24‐053225).